Ptc Therapeutics (PTCT) Net Cash Flow (2012 - 2026)

Ptc Therapeutics' Net Cash Flow history runs 15 years deep, the most recent figure standing at -$146.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 121.06% year-over-year to -$146.4 million; the TTM figure through Mar 2026 stood at -$661.2 million (down 171.01% YoY), while the FY2025 annual figure was $180.3 million, down 6.27% from the prior year.
• Net Cash Flow was -$146.4 million for Q1 2026 at Ptc Therapeutics, down from $302.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $695.2 million in Q1 2025 to a low of -$476.4 million in Q2 2025.
• Historically, Net Cash Flow has averaged $37.6 million across 5 years, with a median of -$40.8 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow surged 4371.86% in 2022, then sank 536.62% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $169.4 million in 2022, then soared by 151.35% to $425.8 million in 2023, then tumbled by 37.95% to $264.2 million in 2024, then climbed by 14.41% to $302.2 million in 2025, then plunged by 148.43% to -$146.4 million in 2026.
• The last three Net Cash Flow figures came in at -$146.4 million (Q1 2026), $302.2 million (Q4 2025), and -$340.7 million (Q3 2025), per Business Quant data.